Lupin achieves GMP certification from TGA Australia for Dabhasa API facility

Lilly partners with API to launch ‘Obesity Gurukul’ in India

The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities

Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly

The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection

Cupid invests in GII Healthcare Investment

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India

Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’

Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease

Senores Pharmaceuticals to increase stake in Havix

Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations

Shilpa Medicare Unit VI facility at Dabaspet receives GMP certification from SFDA

This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product

Merck KGaA bestows 2025 Future Insight Prize to Helmholtz Center’s Magdalena Gotz for breakthroughs in brain regeneration

Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich

Lupin launches nasal spray in US

Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008